zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Michael Thomas, M.D.

Professor of Thoracic Oncology

Head, Department of Internal Medicine, Thoracic Oncology

Thoraxklinik at Heidelberg University Hospital

Röntgenstraße 1

69126 Heidelberg

 

Phone:+49 6221 3961301

 

 

Research Interests:

  • Thoracic Oncology
  • Translation in early trials
  • Tumor microenvironment

 

 

Curriculum Vitae

1979-1985Medical School, University of Gießen, Germany
1986-1987Residency, Ev. Krankenhaus, Gießen, Germany
1988-1992Residency, Medical School, Dpt. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany
1993-1995Senior Fellow, Medical School, Dpt. of Hematology, Oncology and Pneumology, Westfälische Wilhelms University, Münster, Germany
1996-2000Consultant Medical School, Dpt. of Hematology, Oncology and Pneumology, Westfälische Wilhelms University, Münster, Germany
1997-2003Associate Professor, Medical School, Dpt. of Hematology, Oncology and Pneumology, Westfälische Wilhelms University, Münster, Germany
2000Visting Professor, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania, USA
2003-2005Senior Consultant Medical School, Dpt. of Hematology, Oncology and Pneumology, Westfälische Wilhelms University, Münster, Germany
2004-2005Full Professor, Internal Medicine - Pneumology, Medical School, Westfälische Wilhelms University, Münster, Germany
Since 2005Head, Department of Internal Medicine, Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Germany
Since 2005Full Professor, Internal Medicine, Thoracic Oncology, Medical School, Ruprecht-Karls-University Heidelberg, Germany
2006Zusatzbezeichnung Palliativmedizin
2010 - 2016Sprecher Arbeitsgemeinschaft Pneumologische Onkologie der Dt. Krebsgesellschaft
seit 2011Sprecher der Disease Area Lung Cancer im Deutschen Zentrum für Lungenforschung der BMBF geförderten "Gesundheitszentren" (Excellenzcluster)
seit 2015Mitglied im NCT-Direktorium (Nationales Centrum für Tumorerkrankungen), Heidelberg.

 

 

Speciality certification

1992Internal Medicine - Board Certification
1994Hematology and Oncology - Board Certification
1996Pneumology - Board Certification
2001Intensive Care - Board Certification
2006Palliative Care - Board Certifiaction

Honours & Awards

2002AIO–German Cancer Society Award for outstanding achievements in the clinical research of cancer treatment
2010John-Mendelsohn - Clinical Trial Award  -  German Cancer Society

Memberships/Committee Assignments

1995-2003Head Coordinator, German Lung Cancer Cooperative Group (GLCCG)
1998-2006Chair, Respiratory Oncology Section, German Society of Pulmonary Medicine    
Since 2000Thoracic Oncology Working Group, German Cancer Society
2007-2009Board of Directors, German Society of Pulmonary Medicine
2009President, Annual Congress of the German Society of Pulmonary Medicine
Since 2010Chair, Section of Respiratory Oncology, German Cancer Society

Projects

  1. Translational clincial research platform in thoracic oncology. Innovative approaches to guide treatment and to monitor efficacy and resistance are explored in investigator initiated trials. A long standing expertise in the design and conduct of trials in thoracic oncology is utilized to link basic with translational research.

  2. Cohort assembly approaches in thoracic oncology. Cohorts based on sequential biomaterial acquisition and meticulous biomaterial procurement at each state of disease progression have been established. Biomaterials are integrated in research projects elucidating early metatastatic spread, resistance and tumor heterogeneity.

  3. Self-efficacy, coping capabilities and personal growth in metastatic lung cancer with limited life span. In a randomized phase III-trial the impact of physical activity on self-efficacy, coping capabilities, physical fitness, biomarkers of immune response and phenotype of sarkopenia is explored (POSITIVE; Physical Exercise Programm in Lung Cancer Patients with non-operable Disease, undergoing Palliative Treatment; Funding German Cancer Aid; DKH110116).

Team

Project Manager

Dr. rer. nat. Sabine Wessels

Opens window for sending emailE-mail

 

Oncology Consultant

Dr. med. Petros Chrisatopoulos

Dr. med. Barbara Grün

Dr. med. Farustuk Bozorgmehr

Dr. med. Ton Nguyen

 

Study Nurse

Ingrid Heinzmann-Groth

 

M.D. Students

Anja Riediger

Selected Publications

  1. Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M,, Witt C, Kollmeier J, Müller E, Schenk M, Schroeder M, Villalobos M, Reinmuth N, Penzel R,  Schnabel P,  Acker T, Reuss A, Wolf M, on behalf of the ABC-Lung Cancer Group: Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected non squamous non-small cell lung cancer. Eur Respir J 2015, in prerss.

  2. Reinmuth N, Stumpf A, Stumpf P, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Warth A, Bischoff H, Thomas M: Characteristics and outcome of patients with second primary lung cancer. Eur Respir J. 2013; 42:1668-1676.

  3. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M: Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology 2013, 22: 986-992.

  4. Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M: Phase I and pharmacokinetíc study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009,  15: 382-389.

  5. Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, Willich N, Hamm M, Sybrecht GW, Ukena D, Deppermann KM, Dröge C, Riesenbeck D, Heinecke A, Sauerland C, Junker K, Berdel WE, Semik M, for the German Lung Cancer Cooperative Group: Impact of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncology  2008, 9: 636-648.
Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen